SYMBOL:

    Up to 100 tickers separated by a space .....Watch Pre-Market activities
Site Map FAQ Contact us Home Personalize
Company
Industry
Earnings
US Markets
Most Active
Portfolio
Tools
ETFs
Ratings
IDENIX PHARMACEUTICALS
(NQNM:IDIX Last Sale: 5.02 )
Fundamentals Charts Tech Analysis Industry Earnings
Company Profile   Details

Company Web Site
NQNM: (IDIX : $5.02)
$297 million Market Cap at September 12, 2013
Employs 125.
Biomedics SubIndustry up .00% / Health Industry up .00% Today
60 Hampshire Street Research Report Earnings Snapshot - Last 07/31/18
Cambridge, MA 02139 Fact Sheet
Phone: (617) 250-3100 Financial Statements
Peer Comparison
Annual Reports

Jean-Pierre Sommadossi, Chmn./Pres./CEO, David A. Arkowitz, CFO
Focused on hepatitis B virus, or HBV, hepatitis C virus, or HCV. Formerly, NOVIRIO PHARMACEUTICALS LTD. IPO at $14 July 21, 2004. Raised $81.2 million, selling 5.8 million shares, 12% of the outstanding. Lead Manager: Goldman Sachs. Secondary sold 8.2 million shares at $20.61 October 26, 2005, raising $150 million.
Historical Charts    Technical Analysis
No Historical Data available for IDIX

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)
Common IDIX $5.02 $ 0 $4.76 $5.02 1,370,552 $3.15 $6.08 59,077
Capitalization
Earnings Summary ()
*** No Earnings Available***
-10121
Common Stock $296,567

A
Google



QUICK NAVIGATION SITE SEARCH   Enter Keyword:
   
Home    Subscribe    Browser Help    Subscriber Services    B-to-B    Banks    Brokerage    Telco    Site Map    Legal    Contact/Email
Copyright © 1996 - 2024 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex